Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Alexion fortifies rare blood disorder drugs business

Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.

Read More »

Indivior raises forecasts on Suboxone strength

Indivior Plc raised the company’s full-year 2019 forecasts as the embattled British drugmaker’s best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.

Read More »

SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO

Vir Biotechnology priced the company’s initial public offering (IPO) at $20 a share, at the bottom end of expectations, the latest underwhelming investment performance for a stock held by SoftBank Group Corp.’s Vision Fund.

Read More »

Belgium’s UCB to buy Ra Pharmaceuticals

UCB will acquire U.S.-based Ra Pharmaceuticals in a $2.1 billion deal that will enable the Belgian drugmaker to offer new treatment options for several rare diseases in neurology and immunology.

Read More »

Tocagen Cuts 65 Percent of Employees

Less than a month after the company’s Phase III brain cancer treatment failed, San Diego-based Tocagen is undergoing a restructuring and will reduce the employee workforce by 65 percent.

Read More »

Mylan to pay $30 million U.S. SEC fine related to EpiPen overcharge probe

Mylan NV agreed to settle U.S. SEC charges that the company hid from investors the impact of a federal probe into the drugmaker’s overbilling the government for the EpiPen allergy treatment.

Read More »

Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial

Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent.

Read More »

India bans e-cigarettes as global backlash at vaping gathers pace

India banned the sale of electronic cigarettes and warned of an “epidemic” among young people, in the latest and potentially biggest move globally against vaping over growing health concerns.

Read More »

Sanofi to pay Lexicon for terminated partnership

Lexicon Pharmaceuticals Inc. said France’s Sanofi SA will pay the Texas-based drugmaker $260 million for the termination of their partnership to develop the diabetes drug Zynquista.

Read More »

Neurotrope shares crash after Alzheimer’s drug fails in trial

Neurotrope Inc.’s shares tumbled nearly 80 percent after the company said the drug developer’s experimental Alzheimer’s disease treatment Bryostatin-1 did not meet the main goal of a mid-stage study.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom